Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Benefits of Judicial Assistance Dogs for Child Victims in Child Advocacy and Pediatric Assessment Units (UAPEDs) (AudiCAJ)

3 settembre 2026 aggiornato da: Centre Hospitalier Régional d'Orléans

Child maltreatment is common and encompasses various forms, including psychological, physical, and sexual abuse, exposure to domestic violence, neglect, and sexual exploitation. Each year, French police and gendarmerie services record more than 50,000 child victims of intrafamilial violence, according to data from the Ministerial Statistical Service for Internal Security (SSMSI). Approximately two-thirds of these children are victims of physical violence and one-third are victims of sexual violence. These figures have increased steadily over recent years, particularly for sexual violence, in the context of greater disclosure by victims. Violence against children constitutes a major public health issue because of its short- and long-term physical, psychological, and developmental consequences, as well as the increased risk of involvement in future violence during adolescence or adulthood, either as victims or perpetrators.

Children presumed to be victims of abuse are managed in Child Advocacy and Pediatric Assessment Units (Unités d'Accueil Pédiatrique Enfance en Danger, UAPEDs) by multidisciplinary teams comprising physicians, psychologists, nurses, and social workers, following judicial referral or concerns raised by parents or caregivers. Depending on the circumstances, the child may undergo a forensic interview conducted on-site by law enforcement officers (police or gendarmerie), followed by a medico-legal and/or psychological assessment to evaluate the impact of the alleged abuse. This model enables comprehensive care to be delivered in a single location and within a limited timeframe, with professionals working around the child, thereby minimizing repeated disclosures and reducing the risk of retraumatization. The vast majority of forensic interviews are conducted by investigators trained in the National Institute of Child Health and Human Development (NICHD) protocol for interviewing children.

It has been hypothesized that the involvement of a Judicial Assistance Dog (JAD) may provide benefits to children during forensic interviews, a key stage of the judicial process that can be highly stressful for child victims of abuse who are asked to recount traumatic experiences to an unfamiliar investigator.

For centuries, dogs have been domesticated to accompany humans. Since the late twentieth century, they have been specifically trained to assist vulnerable individuals, support people with chronic conditions, and participate in animal-assisted interventions. The role of dogs as part of healthcare and psychosocial support has been extensively studied in recent years. Animal-assisted interventions have been used in a variety of clinical settings with the aim of reducing anxiety, pain, and stress-related symptoms through mechanisms involving emotional regulation and attentional processes. Several studies have reported benefits among children with mental health conditions, including post-traumatic stress disorder (PTSD), depression, attention-deficit/hyperactivity disorder (ADHD), anxiety disorders, and problematic video gaming behaviors. Assistance dogs are also frequently incorporated into interventions for children with autism spectrum disorder to promote prosocial behaviors, with beneficial interactions observed regardless of the child's verbal communication abilities. In pediatric hospital settings, animal-assisted therapy has been associated with reductions in both blood pressure and pain levels.

These effects may be mediated by physiological mechanisms. Exposure to a dog for 15 minutes has been associated with significant reductions in cortisol levels (13), while human-dog interactions have also been linked to changes in electroencephalographic activity and heart rate, potentially enhancing shared attention and emotional regulation.

The concept of the Judicial Assistance Dog first emerged in the United States in the early 2000s within court settings. In France, following a model similar to that developed in North America, the first Judicial Assistance Dog, named Lol, joined the Cahors Court of Justice in 2019 to support victims throughout judicial proceedings. Orko, the second Judicial Assistance Dog trained in France, joined the Child Advocacy and Pediatric Assessment Unit of Orléans University Hospital in 2020.

Several potential benefits of Judicial Assistance Dogs during forensic interviews have been suggested, including reductions in signs of distress and anxiety among child victims. A study conducted in the United States demonstrated significant decreases in heart rate and blood pressure among presumed child victims of sexual abuse who were accompanied by an assistance dog during the forensic process.

Panoramica dello studio

Descrizione dettagliata

This study aims to measure the anxious state of the minor when he first arrives at the unit (T0) and 10 minutes later (T1) with or without the presence of a Judicial Assistance Dog (JAD).

The minor is randomized in one of the two groups of the study:

  • the interventional group (minor in the dedicated waiting room with the JAD for 10min)
  • or the control group (minor in the dedicated waiting room without the JAD for 10min).

Then an anxiety measure occurs. Two time point are evaluated: at arrival (T0) and after waiting 10min (T1):

  1. Anxiety questionnaire: STAI-C translated in French answered with the help of a registered nurse trained for psychometric tests (10 min)
  2. Anxiety level self-assessment (2 min)
  3. Cardiac frequency measure by the registered nurse in charge of the minor (5 min): an average of 3 measures will be taken

Tipo di studio

Interventistico

Iscrizione (Stimato)

46

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

      • Orléans, Francia, 45067
        • Centre Hospitalier Universitaire d'Orléans

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Bambino

Accetta volontari sani

No

Descrizione

Inclusion Criteria:

  1. First-time interview in a child advocacy and pediatric assessment unit (UAPED)
  2. Age ≥ 7 years
  3. Ability to understand and complete the Stat-trait Anxiety Inventory for Children (STAI-C)
  4. Written informed consent obtained from the child's legal guardian

Exclusion Criteria:

  1. Previous contact with the Judicial Assistant Dog
  2. Known dog allergy
  3. Lack of informed consent from the legal guardian
  4. Lack of assent from the child

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Terapia di supporto
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Judicial Assistance Dog group
Children assigned to this group will have contact with the Judicial Assistance Dog before the forensic interview.
After randomization, the Judicial Assistance Dog will be introduced to the child in the waiting room, and the child will remain in contact with the dog for 10 minutes.
Nessun intervento: Standard waiting room group
Children assigned to this group will undergo the standard pre-interview waiting period without contact with the Judicial Assistance Dog.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
To evaluate the effect of the presence of a Judicial Assistance Dog on the chil's anxiety level prior to the forensic interview.
Lasso di tempo: At T0: Baseline assessment upon arrival At T1: After 10 minutes of waiting
Comparison of the change in STAI-C scores between T1 (after 10 min of waiting) and T0 (baseline assessment upon arrival) between the intervention group (10-minute exposure to the Judicial Assistance Dog) and the control group (10 minutes in a standard waiting room)
At T0: Baseline assessment upon arrival At T1: After 10 minutes of waiting

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
To evaluate the effect of the presence of a Judicial Assistance Dog on heart rate
Lasso di tempo: At T0: Baseline assessment upon arrival At T1: After 10 minutes of waiting
Comparison of the change in heart rate (beats per minute, bpm) between T1 (after 10 minutes of waiting) and T0 (baseline assessment upon arrival) between the intervention group (10-minute exposure to the judicial assistant dog) and the control group (10 minutes in a standard waiting room)
At T0: Baseline assessment upon arrival At T1: After 10 minutes of waiting
To evaluate the effect of the presence of a Judicial Assistance Dog on perceived anxiety
Lasso di tempo: At T0: Baseline assessment upon arrival At T1: After 10 minutes of waiting
Comparison of the change in score on the Anxiety Level Self-Assessment Scale between T1 (after 10 minutes of waiting) and T0 (baseline assessment upon arrival) between the intervention group (10-minute exposure to the judicial assistant dog) and the control group (10 minutes in a standard waiting room).
At T0: Baseline assessment upon arrival At T1: After 10 minutes of waiting

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Sarah EID, Doctor, Centre Hospitalier Universitaire d'Orléans

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 ottobre 2026

Completamento primario (Stimato)

1 aprile 2028

Completamento dello studio (Stimato)

1 aprile 2028

Date di iscrizione allo studio

Primo inviato

3 settembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

3 settembre 2026

Primo Inserito (Effettivo)

10 settembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

10 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

3 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • CHUO-2026-06

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

INDECISO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi